Publications en collaboration avec des chercheurs de Hospital de la Santa Creu i Sant Pau (21)

2024

  1. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  2. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

2023

  1. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  2. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

2019

  1. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831

2017

  1. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2015

  1. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

2014

  1. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  2. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

  3. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

2006

  1. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia

    Bone Marrow Transplantation, Vol. 37, Núm. 1, pp. 33-40

  2. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

    Blood, Vol. 108, Núm. 9, pp. 2928-2936

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743

2000

  1. Tuberculosis after hematopoietic stem cell transplantation: Incidence, clinical characteristics and outcome

    Bone Marrow Transplantation, Vol. 26, Núm. 3, pp. 291-298

  2. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: The Spanish experience

    Haematologica, Vol. 85, Núm. 5, pp. 530-538